Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158223 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
NCT00158223 is a Phase 4 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 76 participants.
The verdict
NCT00158223, a Phase 4 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
Study Summary
This study will assess the effectiveness of pimozide in enhancing the effects of clozapine in the treatment of schizophrenia.
Interventions
- DRUG Placebo
- DRUG Pimozide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2004-10 |
| Est. Completion | 2009-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00158223
The ClinicalTrials.gov registry entry for NCT00158223 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00158223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00158223 about?
NCT00158223 is a clinical study titled "Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia". This study will assess the effectiveness of pimozide in enhancing the effects of clozapine in the treatment of schizophrenia.
What is the current status of trial NCT00158223?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2004-10. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00158223?
The interventions under investigation include: Placebo (DRUG), Pimozide (DRUG).
Who is sponsoring clinical trial NCT00158223?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.